TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Techne Corp (TECH) is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to enter now. The stock has mixed-to-bearish near-term signals: the trend is still below key longer averages, analysts have recently cut targets after a weak Q3 result and soft Q4 outlook, and both hedge funds and insiders are net sellers. While RBC and some other firms remain positive on the longer-term biotech funding recovery and the Wilson Wolf acquisition, the current setup does not show a clean entry. My direct view: hold off for now rather than buy immediately.
TECH is showing short-term momentum improvement but the broader trend remains weak. MACD is positive and expanding, which supports near-term upside momentum. However, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is still in a longer-term downtrend or recovery phase rather than a confirmed uptrend. RSI_6 at 72.016 is elevated and suggests the stock is already near overbought conditions, even though the dataset labels it neutral. Price at 50.81 is just above pivot 47.039 and near resistance R1 50.101, with the next resistance at 51.992. That means upside exists, but the chart is not offering a strong low-risk entry for a long-term buyer right now.
RBC Capital resumed coverage with an Outperform rating and a $62 target, citing confidence in sales growth rebound and the underappreciated Wilson Wolf acquisition. Deutsche Bank still has a Buy rating with a $66 target. The company also appears positioned to benefit if biotech funding conditions continue improving. Short-term options volume is call-heavy, which supports some near-term bullish sentiment. No news in the recent week means there is no fresh negative headline pressure.
Recent analyst target cuts were broad and sharp after a Q3 organic growth miss and a weaker-than-expected Q4 guide. Stifel and Baird moved to Hold/Neutral with targets near the current price, signaling limited upside in the near term. Hedge funds are selling heavily, and insiders are also selling, both of which are negative sentiment signals. Congress trading over the last 90 days also shows 1 sale and 0 purchases, adding another cautious signal. The stock trend model also points to weakness over the next month.
Latest quarter data was not available due to the snapshot error, so a full financial review is limited. However, the analyst notes indicate that the company reported a Q3 organic growth miss and guided Q4 to flat organic growth, which is below expectations. That implies recent revenue growth has slowed and the latest quarter season was weak relative to consensus. The market reaction and the multiple analyst target cuts confirm that the most recent quarter was disappointing.
Analyst sentiment is mixed but recently weakened. Positive calls remain from RBC, Deutsche Bank, Citi, and Wells Fargo, with targets ranging from $62 to $70, implying some upside from the current price. However, multiple firms cut targets on May 7 after the Q3 miss and lowered FY26 guidance expectations, including Stifel to $50, Baird to $49, Evercore to $50, and Wells Fargo to $62. The Wall Street pros and cons view is split: bulls argue for a biotech funding recovery and long-term recovery potential, while bears point to weak organic growth, softer biotech demand, and reduced guidance. Net takeaway: sentiment is supportive only for a patient recovery thesis, not for an impatient buy-now long-term entry.
